Track accepted paper

CiteScore: 4.06ℹ
CiteScore measures the average citations received per document published in this title. CiteScore values are based on citation counts in a given year (e.g. 2015) to documents published in three previous calendar years (e.g. 2012 – 14), divided by the number of documents in these three previous years (e.g. 2012 – 14).

Impact Factor: 3.862ℹImpact Factor:2017: 3.862The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
2017 Journal Citation Reports (Clarivate Analytics, 2018)

5-Year Impact Factor: 4.229ℹFive-Year Impact Factor:2017: 4.229To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years.
2017 Journal Citation Reports (Clarivate Analytics, 2018)

Source Normalized Impact per Paper (SNIP): 1.270ℹSource Normalized Impact per Paper (SNIP):2017: 1.270SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.

SCImago Journal Rank (SJR): 1.172ℹSCImago Journal Rank (SJR):2017: 1.172SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.

Author StatsℹAuthor Stats:Publishing your article with us has many benefits, such as having access to a personal dashboard: citation and usage data on your publications in one place. This free service is available to anyone who has published and whose publication is in Scopus.

M. Khan

Dr. Mansoor A. Khan has served FDA for over 11 years as the Director of Product Quality Research and a Senior Biomedical Research Scientist (SBRS) at CDER, where he helped develop regulatory policies for reviews and compliance, and led cmc review and research teams on drug delivery systems, product stability, biotech products, and biopharmaceutics. In Sept of 2015, he joined Texas A&M University as Professor and Vice Dean at the Rangel College of Pharmacy in College Station, TX, where he also currently serves as the Interim Department Head of Pharmaceutical Sciences. Prior to joining FDA in 2004, Dr. Khan was a Professor of Pharmaceutics and Director of Graduate Program in the School of Pharmacy at Texas Tech University Health Science Center. He earned his Ph.D. degree in Industrial Pharmacy from the St. John's University School of Pharmacy at New York in 1992. He has published over 290 peer-reviewed manuscripts, five texts including “Quality by Design for Biopharmaceutical Drug Product Development, 25 book chapters, 200 poster presentations, and more than 250 invited presentations world-wide.

Dr. Khan has held several leadership positions at the American Association of Pharmaceutical Scientists (AAPS) including elected chair of pharmaceutics and drug delivery (PDD) and the founding chair of formulations design and development (FDD). He serves on the editorial board of Pharmaceutical Technology, International Journal of Pharmaceutics, AAPSPharmsciTech, and Drug Delivery and Translational Research. As a formulations expert, Dr. Khan served as a FDA representative to EMA/PDCO, WHO, USP, NIH, DoD, DARPA, NASA, and Bill and Melinda Gates Foundation. He also served as the science policy advisor to CDER Center Director where he helped resolve complex issues of drug reviews and compliance with science. He has also led the chemistry review team that approved the first 3D printed tablets in August 2015. Dr. Khan has received outstanding alumni award from St. Johns University, College of Phamacy, Excellence Award from Texas A&M University Health Science Center, over fifteen FDA/CDER Team Excellence Awards, FDA/CDER Scientific Achievement Award, and FDA/CDER Exemplary Performance Awards. Additionally he received the AAPS Research Achievement Award in Formulations Design and Development. He is also an AAPS and AAiPS Fellow.